

# NHS Greater Glasgow and Clyde: New Medicines Decisions

## January 2016 to present

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

### How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

#### What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

#### What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

#### Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

#### What happens if a particular medicine is not routinely available in NHSGG&C?

- If a medicine is not routinely available and included in the GGC Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. NHSGG&C and all health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Greater Glasgow and Clyde's decisions on new medicines. If you need more information on medicines decisions in NHS Greater Glasgow and Clyde, please email [ggc.medicines@ggc.scot.nhs.uk](mailto:ggc.medicines@ggc.scot.nhs.uk)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>5-aminolaevulinic acid</b> topical gel Ameluz® 1260/17	Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults.  <a href="http://www.scottishmedicines.org.uk/files/advice/5-aminolaevulinic_acid_Ameluz_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/5-aminolaevulinic_acid_Ameluz_FINAL_July_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>Abatacept</b> injection Orencia® 1230/17	Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.	Not routinely available as not recommended for use in NHSScotland	24/04/2017
<b>Abatacept, Adalimumab, Etanercept, Tocilizumab</b>  TA373	Juvenile idiopathic arthritis - various licences with differing age limits	Routinely available in line with national guidance	22/02/2016
<b>Adalimumab</b> injection Humira® 1209/16	Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1209_16_adalimumab_Humira/adalimumab_Humira_Non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1209_16_adalimumab_Humira/adalimumab_Humira_Non_submission</a>	Not routinely available as not recommended for use in NHSScotland	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Adalimumab</b> injection Humira® 1208/16	Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1208_16_adalimumab_Humira/adalimumab_Humira_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1208_16_adalimumab_Humira/adalimumab_Humira_Non-submission</a>	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Adalimumab</b> injection Humira® 1143/16	Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.	Routinely available in line with national guidance	13/06/2016
<b>Adalimumab</b> sub-cutaneous injection Humira® 1173/16	Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08).  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1173_16_adalimumab_Humira/adalimumab_Humira">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1173_16_adalimumab_Humira/adalimumab_Humira</a>	Not routinely available as not recommended for use in NHSScotland	22/08/2016
<b>Afatinib</b> tablets Giotrif® 1174/16	As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1174_16_afatinib_Giotrif/afatinib_Giotrif">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1174_16_afatinib_Giotrif/afatinib_Giotrif</a>	Not routinely available as not recommended for use in NHSScotland	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Aflibercept</b> injection Eylea® 1186/16	For adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).  <a href="http://www.scottishmedicines.org.uk/files/advice/aflibercept_Eylea_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/aflibercept_Eylea_FINAL_Sept_2016_for_website.pdf</a>	Routinely available in line with national guidance	10/10/2016
<b>Albiglutide</b> pre-filled pen Eperzan® 1024/15	Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.	Routinely available in line with national guidance	22/02/2016
<b>Alectinib hydrochloride</b> capsules Alecensa® 1257/17	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.	Not routinely available as not recommended for use in NHSScotland	19/06/2017
<b>Alendronic acid</b> effervescent tablet Binosto® 1137/16	Treatment of postmenopausal osteoporosis.	Routinely available in line with national guidance	18/04/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Alirocumab</b> pre-filled pen <b>Praluent®</b> 1147/16	adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent</a>	Routinely available in line with local or regional guidance  10/10/2016	12/12/2016
<b>Ataluren</b> oral suspension <b>Translarna®</b> 1131/16	Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Not routinely available as not recommended for use in NHSScotland	18/04/2016
<b>Azacitidine</b> injection <b>Vidaza®</b> 1175/16	Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1175_16_azacitidine_Vidaza/azacitidine_Vidaza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1175_16_azacitidine_Vidaza/azacitidine_Vidaza</a>	Not routinely available as not recommended for use in NHSScotland	22/08/2016
<b>Belimumab</b> infusion <b>Benlysta®</b> 775/12	Add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy.  <a href="http://www.scottishmedicines.org.uk/files/advice/belimumab_Benlysta_Resub_FINAL_April_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/belimumab_Benlysta_Resub_FINAL_April_2017_for_website.pdf</a>	Routinely available in line with national guidance	19/06/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Bevacizumab</b> infusion <b>Avastin®</b> 1135/16	In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.	Routinely available in line with local or regional guidance	13/06/2016
<b>Bevacizumab</b> infusion <b>Avastin®</b> 1190/16	In combination with erlotinib for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.	Not routinely available as not recommended for use in NHSScotland	10/10/2016
<b>Biologic agents (See below)</b>  MTA 383	Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) : medicines are adalimumab, certolizumab, etanercept, infliximab, golimumab	Routinely available in line with national guidance	18/04/2016
<b>Biologic agents (see below)</b>  MTA 375	Rheumatoid arthritis (medicines are adalimumab, etanercept, infliximab, certolizumab, golimumab, abatacept, tocilizumab)	Routinely available in line with national guidance	18/04/2016

[http://www.scottishmedicines.org.uk/files/advice/bevacizumab\\_Avastin\\_Non\\_Sub\\_FINAL\\_August\\_2016\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2016_for_website.pdf)

<https://www.nice.org.uk/guidance/ta383>

<https://www.nice.org.uk/guidance/ta375>



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Budesonide/Formoterol</b> inhaler Symbicort® 1198/16	Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.	Not routinely available as not recommended for use in NHSScotland	10/10/2016
	<a href="http://www.scottishmedicines.org.uk/files/advice/budesonide_formoterol_Symbicort_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/budesonide_formoterol_Symbicort_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>		
<b>Buprenorphine</b> oral lyophilisate Espranor® 1245/17	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction.	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	19/06/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/buprenorphine_oral_lyophilisate_Espranor_Abb_FINAL_May_2017_amended_050617_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/buprenorphine_oral_lyophilisate_Espranor_Abb_FINAL_May_2017_amended_050617_for_website.pdf</a>		
<b>Buprenorphine</b> transdermal patch Butec® 1213/17	In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.	Routinely available in line with local or regional guidance	20/02/2017
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1213_17_buprenorphine_transdermal_patch_Butec/buprenorphine_transdermal_patch">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1213_17_buprenorphine_transdermal_patch_Butec/buprenorphine_transdermal_patch</a>		
<b>Cabazitaxel</b> infusion Jevtana® 735/11	In combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.	Routinely available in line with local or regional guidance	12/12/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/735_11_cabazitaxel_Jevtana/cabazitaxel_Jevtana_2nd_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/735_11_cabazitaxel_Jevtana/cabazitaxel_Jevtana_2nd_Resub</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Cabazitaxel</b> infusion Jevtana® 735/11	In combination with prednisone or prednisolone, is indicated for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Cabozantinib</b> tablets Cabometyx® 1234/17	For the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.	Routinely available in line with local or regional guidance	19/06/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/cabozantinib_Cabometyx_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/cabozantinib_Cabometyx_FINAL_May_2017_for_website.pdf</a>		
<b>Calcipotriol, betamethasone</b> cutaneous foam Enstilar® 1182/16	Topical treatment of psoriasis vulgaris in adults	Routinely available in line with national guidance	10/10/2016
	<a href="http://www.scottishmedicines.org.uk/files/advice/calcipotriol_betamethasone_Enstilar_Abb_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/calcipotriol_betamethasone_Enstilar_Abb_FINAL_August_2016_for_website.pdf</a>		
<b>Camellia sinensis (green tea) leaf</b> extract Catephen® 1133/16	Cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years.	Routinely available in line with national guidance	18/04/2016
	<a href="http://http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Canagliflozin, dapagliflozin, empagliflozin</b> oral  MTA 390	as monotherapy for type 2 diabetes in adults for whom use of metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control  <a href="https://www.nice.org.uk/guidance/ta390">https://www.nice.org.uk/guidance/ta390</a>	Routinely available in line with national guidance	22/08/2016
<b>Canakinumab</b> injection <b>Ilaris®</b> 1210/16	Treatment of active Still's disease including Adult-Onset Still's Disease who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1210_16_canakinumab_Ilaris/canakinumab_Ilaris_non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1210_16_canakinumab_Ilaris/canakinumab_Ilaris_non_submission</a>	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Canakinumab</b> injection <b>Ilaris®</b> 1268/17	Treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: - tumour necrosis factor receptor associated periodic syndrome - hyperimmunoglobulin D syndrome / mevalonate kinase deficiency - Familial Mediterranean Fever  <a href="http://www.scottishmedicines.org.uk/files/advice/canankinumab_Ilaris_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/canankinumab_Ilaris_Non_Sub_FINAL_July_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>Capsaicin</b> cutaneous patch <b>Qutenza®</b> 1140/16	Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain.	Not routinely available as not recommended for use in NHSScotland	18/04/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Carfilzomib</b> infusion Kyprolis® 1242/17  <a href="http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_July_2017_for_website.pdf</a>	In combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Routinely available in line with local or regional guidance	28/08/2017
<b>Carfilzomib</b> infusion Kyprolis® 1171/16  <a href="http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_August_2016_revised_080916_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_August_2016_revised_080916_for_website.pdf</a>	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as not recommended for use in NHSScotland	10/10/2016
<b>Carfilzomib</b> infusion Kyprolis® 1171/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1171_16_carfilzomib_Kyprolis/carfilzomib_Kyprolis_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1171_16_carfilzomib_Kyprolis/carfilzomib_Kyprolis_Resub</a>	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Ceftolozane with Tazobactam</b> infusion Zerbaxa® 1146/16	Treatment of the following infections in adults: - Complicated intra-abdominal infections - Acute pyelonephritis - Complicated urinary tract infections	Not routinely available as not recommended for use in NHSScotland	13/06/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Cefuroxime</b> intracameral injection  Aprokam®  932/13  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/932_13_cefuroxime_sodium_Aprokam/cefuroxime_Aprokam_Abbreviated">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/932_13_cefuroxime_sodium_Aprokam/cefuroxime_Aprokam_Abbreviated</a>	Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.	Routinely available in line with national guidance	12/12/2016
<b>Certolizumab and Secukinumab</b>       TA445  <a href="https://www.nice.org.uk/guidance/ta445">https://www.nice.org.uk/guidance/ta445</a>	Active psoriatic arthritis after inadequate response to DMARDs	Routinely available in line with national guidance	28/08/2017
<b>Certolizumab pegol</b> injection  Cimzia®  1155/16	Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Ciprofloxacin with Dexamethasone</b> ear drops  Cilodex®  1256/17  <a href="http://www.scottishmedicines.org.uk/files/advice/ciprofloxacin-dexamethasone_Cilodex_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ciprofloxacin-dexamethasone_Cilodex_Abbreviated_FINAL_June_2017_for_website.pdf</a>	Treatment of the following infections in adults and children: - Acute otitis media in patients with tympanostomy tubes (AOMT) - Acute otitis externa	Routinely available in line with national guidance	28/08/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Cobimetinib</b> tablets Cotellic® 1191/16  <a href="http://www.scottishmedicines.org.uk/files/advice/cobimetinib_Cotellic_Non_Sub_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/cobimetinib_Cotellic_Non_Sub_FINAL_August_2016_for_website.pdf</a>	In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Not routinely available as not recommended for use in NHSScotland	10/10/2016
<b>Co-careldopa</b> intestinal gel Duodopa® 316/06	Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.	Routinely available in line with national guidance	13/06/2016
<b>Crizotinib</b> hard capsules Xalkori® 1152/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1152_16_crizotinib_Xalkori/crizotinib_Xalkori">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1152_16_crizotinib_Xalkori/crizotinib_Xalkori</a>	First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).	Routinely available in line with local or regional guidance	22/08/2016
<b>Daclizumab</b> pre-filled syringe or pen Zinbryta® 1216/17	In adult patients for the treatment of relapsing forms of multiple sclerosis.	Routinely available in line with national guidance	24/04/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Dalbavancin</b> infusion  Xydalba®  1105/15  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1105_15_dalbavancin_Xydalba/dalbavancin_Xydalba">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1105_15_dalbavancin_Xydalba/dalbavancin_Xydalba</a>	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.	Routinely available in line with local or regional guidance	20/02/2017
<b>Daptomycin</b> injection or infusion  Cubicin®  1141/16	Treatment of paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections.	Not routinely available as not recommended for use in NHSScotland	18/04/2016
<b>Daratumumab</b> infusion  Darzalex®  1205/17  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1205_17_daratumumab_Darzalex/daratumumab_Darzalex">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1205_17_daratumumab_Darzalex/daratumumab_Darzalex</a>	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Dasatinib</b> tablets  Sprycel®  1170/16  <a href="http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_FINAL_August_2016_for_website.pdf</a>	The treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase	Routinely available in line with local or regional guidance	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Dasatinib</b> tablets Sprycel® 370/07  <a href="http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_Resub_FINAL_August_2016_Amended_06.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_Resub_FINAL_August_2016_Amended_06.09.16_for_website.pdf</a>	The treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate	Routinely available in line with local or regional guidance	10/10/2016
<b>Deferasirox</b> dispersible tablets Exjade® 347/07  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/347_07_deferasirox_Exjade/deferasirox_Exjade_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/347_07_deferasirox_Exjade/deferasirox_Exjade_Resub</a>	Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate, in adult and paediatric patients aged 2 years and older with rare acquired or inherited anaemias.	Routinely available in line with local or regional guidance	20/02/2017
<b>Deferasirox</b> tablets Exjade® 1246/17  <a href="http://www.scottishmedicines.org.uk/files/advice/deferasirox_Exjade_Abbreviated_FINAL_May_2017_Amended_050617_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/deferasirox_Exjade_Abbreviated_FINAL_May_2017_Amended_050617_for_website.pdf</a>	Treatment of chronic iron overload due to frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older and treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in specific patient groups as outlined in full in the SMC advice.	Routinely available in line with national guidance	19/06/2017
<b>Dequalinium chloride</b> vaginal tablets Floumizin® 1194/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Fluomizin/dequalinium_Fluomizin">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Fluomizin/dequalinium_Fluomizin</a>	Treatment of bacterial vaginosis.	Routinely available in line with national guidance	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Desmopressin</b> oral lyophilisate Noqdirna® 1218/17	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults  <a href="http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf</a>	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  19/02/2018	28/08/2017
<b>Desmopressin</b> oral lyophilisate Noqdirna® 1218/17	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1218_17_desmopressin_Noqdirna/desmopressin_Noqdirna">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1218_17_desmopressin_Noqdirna/desmopressin_Noqdirna</a>	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Diamorphine hydrochloride</b> nasal spray Ayendi® 1172/16	Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1172_16_diamorphine_hydrochloride_Ayendi/diamorphine_hydrochloride_Ayendi">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1172_16_diamorphine_hydrochloride_Ayendi/diamorphine_hydrochloride_Ayendi</a>	Routinely available in line with national guidance	22/08/2016
<b>Dulaglutide</b> injection Trulicity® 1110/15	In adults with type 2 diabetes mellitus to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.	Routinely available in line with national guidance	22/02/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Eculizumab</b> infusion Soliris® 767/12	In adults and children for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS)	Not routinely available as not recommended for use in NHSScotland	22/02/2016
<b>Eculizumab</b> infusion Soliris® 1130/16	In adults and children, for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Not routinely available as not recommended for use in NHSScotland	18/04/2016
<b>Elbasvir and grazoprevir</b> tablets Zepatier® 1203/17	Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1203_17_elbasvir-grazoprevir_Zepatier/elbasvir-grazoprevir_Zepatier">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1203_17_elbasvir-grazoprevir_Zepatier/elbasvir-grazoprevir_Zepatier</a>	Routinely available in line with national guidance	20/02/2017
<b>Elotuzumab</b> infusion Empliciti® 1183/16	Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1183_16_elotuzumab_Empliciti/elotuzumab_Empliciti">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1183_16_elotuzumab_Empliciti/elotuzumab_Empliciti</a>	Not routinely available as not recommended for use in NHSScotland	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Eltrombopag</b> tablets Revolade® 1206/17	Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to 17 years who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  24/04/2017	20/02/2017
<b>Eltrombopag olamine</b> tablets Revolade® 1164/16	Treatment in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1164_16_eltrombopag_olamine_Ravolade/eltrombopag_olamine_Revolade_Non_submi">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1164_16_eltrombopag_olamine_Ravolade/eltrombopag_olamine_Revolade_Non_submi</a>			
<b>Emtricitabine with Tenofovir disoproxil</b> tablets Truvada 1263/17	Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<a href="http://www.scottishmedicines.org.uk/files/advice/emtricitabine-tenofovir_disoproxil_Truvada_Non_Submission_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/emtricitabine-tenofovir_disoproxil_Truvada_Non_Submission_FINAL_June_2017_for_website.pdf</a>			
<b>Emtricitabine/tenofovir alafenamide</b> tablets Descovy® 1169/16	In combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.	Routinely available in line with national guidance	22/08/2016
<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1169_16_emtricitabine_tenofovir_alafenamide_Descovy/emtricitabine_tenofovir_alafena">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1169_16_emtricitabine_tenofovir_alafenamide_Descovy/emtricitabine_tenofovir_alafena</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Emtricitabine/tenofovir disoproxil</b> tablets Truvada® 1225/17	In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.	Routinely available in line with national guidance	24/04/2017
<b>Enzalutamide</b> soft capsules Xtandi 1066/15	Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	Routinely available in line with local or regional guidance	18/04/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1066_15_enzalutamide_Xtandi/Briefing_note_enzalutamide_Xtandi_IRP">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1066_15_enzalutamide_Xtandi/Briefing_note_enzalutamide_Xtandi_IRP</a>		
<b>Eribulin (mesilate)</b> injection Halaven® 1065/15	Treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.	Routinely available in line with local or regional guidance	18/04/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1065_15_eribulin_Halaven/Briefing_note_eribulin_Halaven_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1065_15_eribulin_Halaven/Briefing_note_eribulin_Halaven_Resubmission</a>		
<b>Erlotinib, Gefitinib</b>  TA374	Non-small cell lung cancer post chemotherapy	Routinely available in line with national guidance	22/02/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Everolimus</b> tablets Afinitor® 872/13	Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Routinely available in line with local or regional guidance	18/04/2016
<b>Everolimus</b> tablets Afinitor® 1215/17	Treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1215_17_everolimus_Afinitor/everolimus_Afinitor_NETs">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1215_17_everolimus_Afinitor/everolimus_Afinitor_NETs</a>	Routinely available in line with local or regional guidance	20/02/2017
<b>Everolimus and Sunitinib</b>  MTA 449	Unresectable or metastatic neuroendocrine tumours in people with progressive disease  <a href="https://www.nice.org.uk/guidance/ta449">https://www.nice.org.uk/guidance/ta449</a>	Routinely available in line with local or regional guidance	28/08/2017
<b>Evolocumab</b> injection Repatha® PFS 1148/16	In adults with primary hypercholesterolaemia or mixed dyslipidaemia or in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia (see SMC advice for full details of indication)	Not routinely available as not recommended for use in NHSScotland	13/06/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Evolocumab</b> injection <b>Repatha®</b> 1148/16	In adults with primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia, as an adjunct to diet: [1] in combination with a statin or statin with other lipid lowering therapies in patients unable to reach low density lipoprotein-cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or, [2] alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1148_16_evolocumab_Repatha/evolocumab_Repatha_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1148_16_evolocumab_Repatha/evolocumab_Repatha_Resub</a>	Routinely available in line with local or regional guidance	20/02/2017
<b>Fampridine</b> prolonged-release tablets <b>Fampyra®</b> 789/12	For the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7).  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/789_12_fampridine_Fampyra/fampridine_Fampyra">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/789_12_fampridine_Fampyra/fampridine_Fampyra</a>	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Febuxostat</b> tablets <b>Adenuric®</b> 1153/16	Prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS).	Routinely available in line with national guidance	13/06/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Fentanyl</b> transdermal system  <b>Ionsys®</b>  1207/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1207_16_fentanyl_ionsys/fentanyl_ionsys_Non_Submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1207_16_fentanyl_ionsys/fentanyl_ionsys_Non_Submission</a>	Management of acute moderate to severe post-operative pain in adult patients	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Ferric maltol</b> capsules  <b>Feraccru®</b>  1202/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1202_16_ferric_maltol_Feraccru/ferric_maltol_Feraccru">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1202_16_ferric_maltol_Feraccru/ferric_maltol_Feraccru</a>	Treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD).	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Follitropin delta</b> injection  <b>Rekovel®</b>  1269/17  <a href="http://www.scottishmedicines.org.uk/files/advice/follitropin_Rekovel_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/follitropin_Rekovel_Non_Sub_FINAL_July_2017_for_website.pdf</a>	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>Fosfomycin trometamol</b> granules for oral solution  <b>Monuril®</b>  1163/16  <a href="http://www.scottishmedicines.org.uk/files/advice/fosfomycin_trometamol_Monuril_Abbreviated_FINAL_June_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/fosfomycin_trometamol_Monuril_Abbreviated_FINAL_June_2016_for_website.pdf</a>	Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females and prophylaxis in diagnostic and surgical transurethral procedures.	Routinely available in line with local or regional guidance	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Fulvestrant</b> injection <b>Faslodex®</b> 114/04	Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen.	Routinely available in line with local or regional guidance	22/02/2016
<b>Genvoya®</b> tablets <b>Genvoya®</b> 1142/16	Treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.	Routinely available in line with national guidance	13/06/2016
<b>Golimumab</b> sub-cutaneous injection <b>Simponi®</b> 1124/16	Treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).	Routinely available in line with national guidance	22/02/2016
<b>Golimumab</b> injection <b>Simponi®</b> 1199/16	In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate.	Not routinely available as not recommended for use in NHSScotland	10/10/2016
<a href="http://www.scottishmedicines.org.uk/files/advice/golimumab_Simponi_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/golimumab_Simponi_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Guanfacine</b> prolonged-release tablets Intuniv® 1123/16	Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 yrs old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1123_16_guanfacine_hydrochloride_Intuniv/Briefing_note_guanfacine_hydrochloride_Int">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1123_16_guanfacine_hydrochloride_Intuniv/Briefing_note_guanfacine_hydrochloride_Int</a>	Routinely available in line with national guidance	18/04/2016
<b>Human alpha1-proteinase inhibitor</b> infusion Respreeza® 1157/16	Maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor (A1-PI) deficiency.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1157_16_human_alpha_1_proteinase_inhibitor_Respreeza/human_alpha_1_proteinase">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1157_16_human_alpha_1_proteinase_inhibitor_Respreeza/human_alpha_1_proteinase</a>	Not routinely available as not recommended for use in NHSScotland	22/08/2016
<b>Hydrocortisone</b> modified-release tablets Plenadren® 848/12	Treatment of adrenal insufficiency in adults  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/848_12_hydrocortisone_Plenadren/hydrocortisone_Plenadren">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/848_12_hydrocortisone_Plenadren/hydrocortisone_Plenadren</a>	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Hyoscine hydrobromide</b> tablets	Antispasmodic for irritable bowel syndrome		22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ibrutinib</b> capsules Imbruvica® 1258/17	In combination with bendamustine and rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy	Not routinely available as not recommended for use in NHSScotland	19/06/2017
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1258_17_ibrutinib_Imbruvica/ibrutinib_Imbruvica_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1258_17_ibrutinib_Imbruvica/ibrutinib_Imbruvica_Non-submission</a>		
<b>Ibrutinib</b> capsules Imbruvica® 1151/16	Treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	Routinely available in line with local or regional guidance	24/04/2017
<b>Ibrutinib</b> hard capsules Imbruvica® 1150/16	Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).	Routinely available in line with local or regional guidance	22/08/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1150_16_ibrutinib_Imbruvica_MCL/ibrutinib_Imbruvica_MCL">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1150_16_ibrutinib_Imbruvica_MCL/ibrutinib_Imbruvica_MCL</a>		
<b>Ibrutinib</b> hard capsules Imbruvica® 1151/16	Treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.	Routinely available in line with local or regional guidance	22/08/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1151_16_ibrutinib_Imbruvica_CLL/ibrutinib_Imbruvica_CLL">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1151_16_ibrutinib_Imbruvica_CLL/ibrutinib_Imbruvica_CLL</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Idarucizumab</b> injection/infusion Praxbind® 1178/16  <a href="http://www.scottishmedicines.org.uk/files/advice/idarucizumab_Praxbind_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/idarucizumab_Praxbind_FINAL_August_2016_for_website.pdf</a>	Reversal of anticoagulation effect of dabigatran in adults when rapid reversal is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding	Routinely available in line with national guidance	10/10/2016
<b>Idebenone</b> tablets Raxone® 1226/17  <a href="http://www.scottishmedicines.org.uk/files/advice/idebenone_Raxone_FINAL_April_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/idebenone_Raxone_FINAL_April_2017_for_website.pdf</a>	Treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).	Routinely available in line with national guidance	19/06/2017
<b>Idelalisib</b> tablets Zydelig® 1212/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1212_16_idelalisib_Zydelig/idelalisib_Zydelig_Non_Submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1212_16_idelalisib_Zydelig/idelalisib_Zydelig_Non_Submission</a>	In combination with ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy, or first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Insulin aspart</b> injection Fiasp® 1227/17	Treatment of diabetes mellitus in adults.	Routinely available in line with national guidance	24/04/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Insulin degludec</b> pre-filled pen, cartridge Tresiba® 856/13  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/856_13_insulin_degludec_Tresiba/insulin_degludec_Tresiba_2nd_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/856_13_insulin_degludec_Tresiba/insulin_degludec_Tresiba_2nd_Resubmission</a>	Treatment of diabetes mellitus in adults	Routinely available in line with local or regional guidance	22/08/2016
<b>Insulin detemir</b> injection Levemir® 1126/16	Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.	Routinely available in line with national guidance	26/04/2016
<b>Insulin Glargine 300 units/ml</b> pre-filled pen Toujeo® 1078/15  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1078_15_insulin_glargine_Toujeo/insulin_glargine_Toujeo_ABB">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1078_15_insulin_glargine_Toujeo/insulin_glargine_Toujeo_ABB</a>	Treatment of type 1 or type 2 diabetes mellitus in adults aged 18 years and above.	Routinely available in line with local or regional guidance	12/12/2016
<b>Iron (III) isomaltoside 1000</b> injection Diafer® 1177/16  <a href="http://www.scottishmedicines.org.uk/files/advice/iron_isomaltoside_1000_Diafer_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/iron_isomaltoside_1000_Diafer_FINAL_August_2016_for_website.pdf</a>	The treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used.	Not routinely available as not recommended for use in NHSScotland	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Iron III isomaltoside 1000</b> injection Diafer® 1177/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1177_16_iron_isomaltoside_1000_Diafer/iron_III_isomaltoside_1000_Diafer_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1177_16_iron_isomaltoside_1000_Diafer/iron_III_isomaltoside_1000_Diafer_Resub</a>	Treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used.	Routinely available in line with national guidance	20/02/2017
<b>Isavuconazole</b> infusion, hard capsules Cresemba® 1129/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	in adults for the treatment of: -invasive aspergillosis -mucormycosis in patients for whom amphotericin B is inappropriate	Routinely available in line with national guidance	18/04/2016
<b>Ivacaftor</b> granules Kalydeco® 1134/16	Treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25kg who have one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Ivacaftor</b> tablets Kalydeco® 1193/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1193_16_ivacaftor_Kalydeco/ivacaftor_Kalydeco">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1193_16_ivacaftor_Kalydeco/ivacaftor_Kalydeco</a>	Treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CF transmembrane conductance regulator (CFTR) gene.	Not routinely available as not recommended for use in NHSScotland	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ixekizumab</b> injection  Taltz®  1223/17	Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Routinely available in line with national guidance	24/04/2017
<b>Lacosamide</b> tablets, infusion, syrup  Vimpat®  1231/17	As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.	Not routinely available as not recommended for use in NHSScotland	24/04/2017
<b>Lenalidomide</b> capsules  Revlimid®  1211/16	Treatment of adult patients with relapsed or refractory mantle cell lymphoma.	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Lenvatinib</b> capsules  Lenvima®  1179/16	Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).	Routinely available in line with local or regional guidance	10/10/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1211_16_lenalidomide_Revlimid/lenalidomide_Revlimid_non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1211_16_lenalidomide_Revlimid/lenalidomide_Revlimid_non_submission</a>		
	<a href="http://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Levofloxacin</b> nebuliser solution Quinsair® 1162/16	Management of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in adult patients with cystic fibrosis.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1162_16_levofloxacin_Quinsair/levofloxacin_Quinsair">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1162_16_levofloxacin_Quinsair/levofloxacin_Quinsair</a>	Routinely available in line with national guidance	22/08/2016
<b>Liposomal Irinotecan</b> infusion Onivyde® 1217/17	Treatment of metastatic adenocarcinoma of the pancreas, in combination with fluorouracil(5-FU) and leucovorin (folinic acid), in adult patients who have progressed following gemcitabine based therapy.	Not routinely available as not recommended for use in NHSScotland	24/04/2017
<b>Liraglutide</b> injection Saxenda® 1247/17	As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of $\geq 30\text{kg/m}^2$ (obese), or $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1247_17_liraglutide_Saxenda/liraglutide_Saxenda_Non_Sub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1247_17_liraglutide_Saxenda/liraglutide_Saxenda_Non_Sub</a>	Not routinely available as not recommended for use in NHSScotland	19/06/2017
<b>Liraglutide</b> injection Victoza® 1192/16	As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.  <a href="http://www.scottishmedicines.org.uk/files/advice/liraglutide_Victoza_Non_Sub_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/liraglutide_Victoza_Non_Sub_FINAL_August_2016_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Lumacaftor with ivacaftor</b> tablets Orkambi® 1136/16	Treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Mepolizumab</b> injection Nucala® 1149/16	Add-on treatment for severe refractory eosinophilic asthma in adult patients.	Routinely available in line with local or regional guidance	13/06/2016
<b>Micronised progesterone</b> vaginal capsules Utrogestan® 935/13	In women for supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles.	Routinely available in line with national guidance	19/06/2017
<b>Migalastat</b> capsules Galafold® 1196/16	<p>Long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (<math>\alpha</math>-galactosidase A deficiency) and who have an amenable mutation.</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/micronised_progesterone_Utrogestan_Vaginal_FINAL_April_2017_Amended_12.04.17_for_webs">http://www.scottishmedicines.org.uk/files/advice/micronised_progesterone_Utrogestan_Vaginal_FINAL_April_2017_Amended_12.04.17_for_webs</a></p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1196_16_migalastat_Galafold/migalastat_Galafold">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1196_16_migalastat_Galafold/migalastat_Galafold</a></p>	Routinely available in line with national guidance	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>N/A</b> melt-in cream</p> <p><b>Anthelios® XL SPF 50</b></p> <p>Formulary appeal</p>	<p>Skin protection against UVA and UVB rays</p>	<p>Routinely available in line with local or regional guidance</p>	<p>18/04/2016</p>
<p><b>Naproxen</b> effervescent tablets</p> <p><b>Stirlescent®</b></p> <p>1154/16</p>	<p>Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults</p>	<p>Routinely available in line with national guidance</p>	<p>13/06/2016</p>
<p><b>Necitumumab</b> infusion</p> <p><b>Portrazza®</b></p> <p>1184/16</p>	<p>In combination with gemcitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1184_16_necitumumab_Portrazza/necitumumab_Portrazza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1184_16_necitumumab_Portrazza/necitumumab_Portrazza</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>22/08/2016</p>
<p><b>Nepafenac</b> eye drops</p> <p><b>Nevanac®</b></p> <p>1228/17</p>	<p>Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients</p>	<p>Routinely available in line with national guidance</p>	<p>24/04/2017</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Netupitant with Palonosetron</b> capsules Akynzeo® 1109/15	Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in adult patients.	Routinely available in line with local or regional guidance	22/02/2016
<b>Nivolumab</b> infusion Opdivo® 1240/17	Treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.	Routinely available in line with local or regional guidance	28/08/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_cHL_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_cHL_FINAL_June_2017_for_website.pdf</a>		
<b>Nivolumab</b> infusion Opdivo® 1188/16	As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.	Routinely available in line with local or regional guidance	19/06/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_RESUBMISSION_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_RESUBMISSION_FINAL_May_2017_for_website.pdf</a>		
<b>Nivolumab</b> infusion Opdivo® 1188/16	As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.	Not routinely available as not recommended for use in NHSScotland	12/12/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1188_16_nivolumab_Opdivo_for_renal_cell_carcinoma/nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1188_16_nivolumab_Opdivo_for_renal_cell_carcinoma/nivolumab_Opdivo</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Nivolumab</b> infusion Opdivo® 1187/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1187_16_nivolumab_Opdivo_with_ipilimumab_for_melanoma/nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1187_16_nivolumab_Opdivo_with_ipilimumab_for_melanoma/nivolumab_Opdivo</a>	In combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Routinely available in line with local or regional guidance	12/12/2016
<b>Nivolumab</b> infusion Opdivo® 1144/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1144_16_nivolumab_Opdivo_for_metastatic_squamous_NSCLC/nivolumab_Opdivo_for">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1144_16_nivolumab_Opdivo_for_metastatic_squamous_NSCLC/nivolumab_Opdivo_for</a>	Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	Routinely available in line with local or regional guidance	22/08/2016
<b>Nivolumab</b> infusion Opdivo® 1120/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/Briefing_note_nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/Briefing_note_nivolumab_Opdivo</a>	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Not routinely available as not recommended for use in NHSScotland	18/04/2016
<b>Nivolumab</b> infusion Opdivo® 1120/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/nivolumab_Opdivo_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/nivolumab_Opdivo_Resubmission</a>	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Routinely available in line with local or regional guidance	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Nivolumab</b> infusion Opdivo® 1180/16  <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Sept_2016_FINAL_amended_150916_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Sept_2016_FINAL_amended_150916_for_website.pdf</a>	Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	Routinely available in line with local or regional guidance	10/10/2016
<b>Obeticholic acid</b> tablets Ocaliva® 1232/17  <a href="http://www.scottishmedicines.org.uk/files/advice/obeticholic_acid_Ocaliva_FINAL_May_2017_Amended_170517_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/obeticholic_acid_Ocaliva_FINAL_May_2017_Amended_170517_for_website.pdf</a>	Primary biliary cholangitis (alsoknown as primary biliary cirrhosis) in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid	Routinely available in line with local or regional guidance	19/06/2017
<b>Obinutuzumab</b> infusion Gazyvaro® 1219/17`	Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.	Routinely available in line with local or regional guidance	24/04/2017
<b>Oestrogens, conjugated, bazedoxifene acetate</b> modified-release tablets Duavive® 1220/17  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1220_17_oestrogens_coniugated_Duavive/oestrogens_coniugated_Duavive_Non_Sub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1220_17_oestrogens_coniugated_Duavive/oestrogens_coniugated_Duavive_Non_Sub</a>	Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.	Not routinely available as not recommended for use in NHSScotland	20/02/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ofatumumab</b> infusion Arzerra® 1237/17	Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclophosphamide.	Not routinely available as not recommended for use in NHSScotland	24/04/2017
<b>Olaparib</b> capsules Lynparza® 1047/15	Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1047_15_olaparib_Lynparza/olaparib_Lynparza_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1047_15_olaparib_Lynparza/olaparib_Lynparza_Resubmission</a>	Routinely available in line with local or regional guidance	12/12/2016
<b>Oseltamivir</b> powder for oral suspension Tamiflu® 1127/16	Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.	Routinely available in line with national guidance	26/04/2016
<b>Osimertinib</b> tablets Tagrisso® 1214/17	Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC). <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1214_17_osimertinib_Tagrisso/osimertinib_Tagrisso">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1214_17_osimertinib_Tagrisso/osimertinib_Tagrisso</a>	Routinely available in line with local or regional guidance	20/02/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Paliperidone palmitate</b> prolonged-release injection Trevicta® 1181/16	Maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product  <a href="http://www.scottishmedicines.org.uk/files/advice/paliperidone_palmitate_Trevicta_Abb_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/paliperidone_palmitate_Trevicta_Abb_FINAL_August_2016_for_website.pdf</a>	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	10/10/2016
<b>Panitumumab</b> infusion Vectibix® 439	1st line metastatic colorectal cancer in combination with either FOLFOX or FOLFIRI: - cetuximab for EGFR-expressing, RAS wild-type - panitumumab for RAS wild-type in  <a href="https://www.nice.org.uk/guidance/ta439">https://www.nice.org.uk/guidance/ta439</a>	Routinely available in line with local or regional guidance	19/06/2017
<b>Panobinostat</b> hard capsules Farydak® 1122/16	In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.	Routinely available in line with local or regional guidance	22/02/2016
<b>Pegaspargase</b> injection/infusion Oncaspar® 1197/16	As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1197_16_pegaspargase_Oncaspar_/pegaspargase_Oncaspar">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1197_16_pegaspargase_Oncaspar_/pegaspargase_Oncaspar</a>	Routinely available in line with local or regional guidance	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Pembrolizumab</b> infusion Keytruda® 1204/17  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1204_17_pembrolizumab_Keytruda/pembrolizumab_Keytruda">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1204_17_pembrolizumab_Keytruda/pembrolizumab_Keytruda</a>	Treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) and who have received at least one prior chemotherapy regimen.	Routinely available in line with local or regional guidance	20/02/2017
<b>Pembrolizumab</b> infusion Keytruda® 1087/15  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1087_15_pembrolizumab_Keytruda/pembrolizumab_Keytruda_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1087_15_pembrolizumab_Keytruda/pembrolizumab_Keytruda_Resub</a>	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously treated with ipilimumab.	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Pembrolizumab</b> infusion Keytruda 1239/17  <a href="http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_June_2017_for_website.pdf</a>	As monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) with a ≥50% tumour proportion score (TPS) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive tumour mutations.	Routinely available in line with local or regional guidance	28/08/2017
<b>Perampanel</b> tablets Fycompa® 1200/16  <a href="http://www.scottishmedicines.org.uk/files/advice/perampanel_Fycompa_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/perampanel_Fycompa_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>	Adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy	Not routinely available as not recommended for use in NHSScotland	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Pertuzumab</b> infusion</p> <p>Perjeta®</p> <p>1121/16</p>	<p>In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/Briefing_note_pertuzumab_Perjeta">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/Briefing_note_pertuzumab_Perjeta</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>18/04/2016</p>
<p><b>Pertuzumab</b> infusion</p> <p>Perjeta®</p> <p>1121/16</p>	<p>In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/pertuzumab_Perjeta_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/pertuzumab_Perjeta_Resub</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>12/12/2016</p>
<p><b>Pertuzumab</b> infusion</p> <p>Perjeta®</p> <p>897/13</p>	<p>for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/pertuzumab_Perjeta_2nd_Resub_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pertuzumab_Perjeta_2nd_Resub_FINAL_May_2017_for_website.pdf</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>19/06/2017</p>
<p><b>Phenylephrine hydrochloride, tropicamide</b> ophthalmic insert</p> <p>Mydriaserit®</p> <p>Formulary appeal</p>	<p>For use in adult patients to obtain pre-operative mydriasis or for diagnostic purposes when monotherapy is known to be insufficient.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>18/04/2016</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Pitolisant</b> tablets Wakix® 1229/17  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1229_17_pitolisant_Wakix/pitolisant_Wakix">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1229_17_pitolisant_Wakix/pitolisant_Wakix</a>	Treatment of narcolepsy with or without cataplexy in adults	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Pixantrone</b> infusion Pixuvri® 1138/16	Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas	Not routinely available as not recommended for use in NHSScotland	22/02/2016
<b>Progesterone</b> vaginal tablets Lutigest® 1185/16  <a href="http://www.scottishmedicines.org.uk/files/advice/progesterone_Lutigest_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/progesterone_Lutigest_FINAL_Sept_2016_for_website.pdf</a>	Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women	Routinely available in line with national guidance	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ramucirumab</b> infusion <b>Cyramza®</b> 1176/16	<p>- In combination with paclitaxel for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy</p> <p>- As monotherapy for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1176_16_ramucirumab_Cyramza/ramucirumab_Cyramza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1176_16_ramucirumab_Cyramza/ramucirumab_Cyramza</a></p>	Not routinely available as not recommended for use in NHSScotland	22/08/2016
<b>Ramucirumab</b> infusion <b>Cyrmaza®</b> 1156/16	<p>In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine</p>	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Ramucirumab</b> infusion <b>Cyrmaza®</b> 1165/16	<p>In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1165_16_ramucirumab_Cyramza/ramucirumb_Cyramza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1165_16_ramucirumab_Cyramza/ramucirumb_Cyramza</a></p>	Not routinely available as not recommended for use in NHSScotland	13/06/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Rilpivirine</b> tablet Edurant® 1168/16	In combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL.	Routinely available in line with national guidance	22/08/2016
<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1168_16_rilpivirine_hydrochloride_Edurant/rilpivirine_hydrochloride_Edurant">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1168_16_rilpivirine_hydrochloride_Edurant/rilpivirine_hydrochloride_Edurant</a>			
<b>Rilpivirine, Emtricitabine, Tenofovir alafenamide</b> tablets Odefsey® 1189/16	Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.	Routinely available in line with national guidance	10/10/2016
<a href="http://www.scottishmedicines.org.uk/files/advice/rilpivirine_emtricitabine_Odefsey_Abbreviated_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/rilpivirine_emtricitabine_Odefsey_Abbreviated_FINAL_Sept_2016_for_website.pdf</a>			
<b>Ruxolitinib phosphate</b> tablets Jakavi® 1166/16	Treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1166_16_ruxolitinib_as_phosphate_Jakavi/ruxolitinib_Jakavi_Non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1166_16_ruxolitinib_as_phosphate_Jakavi/ruxolitinib_Jakavi_Non_submission</a>			
<b>Sacubitril/Valsartan</b> film coated tablets Entresto® 1132/16	In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.	Routinely available in line with local or regional guidance	18/04/2016
<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1132_16_sacubitril_valsartan_Entresto/Briefing_note_sacubitril_valsartan_Entresto">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1132_16_sacubitril_valsartan_Entresto/Briefing_note_sacubitril_valsartan_Entresto</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Safinamide</b> tablets Xadago® 1259/17	Treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.	Not routinely available as not recommended for use in NHSScotland	19/06/2017
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1259_17_safinamide_Xadago/safinamide_Xadago_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1259_17_safinamide_Xadago/safinamide_Xadago_Non-submission</a>		
<b>Saxagliptin with Dapagliflozin</b> tablets Qtern 1255/17	in adults aged 18 years and older with type 2 diabetes mellitus 1)to improve glycaemic control when metformin and/or sulphonylurea and one of the monocomponents of Qtern® do not provide adequate glycaemic control or 2) when already being treated with the free combination of dapagliflozin and saxagliptin	Routinely available in line with national guidance	28/08/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/saxagliptin-dapagliflozin_Qtern_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/saxagliptin-dapagliflozin_Qtern_Abbreviated_FINAL_June_2017_for_website.pdf</a>		
<b>Secukinumab</b> sub-cutaneous injection Cosentyx® 1159/16	Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.	Routinely available in line with national guidance	22/08/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1159_16_secukinumab_Cosentyx_AS/secukinumab_Cosentyx">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1159_16_secukinumab_Cosentyx_AS/secukinumab_Cosentyx</a>		
<b>Secukinumab</b> sub-cutaneous injection Cosentyx® 1167/16	alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.	Routinely available in line with national guidance	22/08/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1167_16_secukinumab_Cosentyx/secukinumab_Cosentyx">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1167_16_secukinumab_Cosentyx/secukinumab_Cosentyx</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Selexipag</b> tablets Uptravi 1235/17	For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II to III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies  <a href="http://www.scottishmedicines.org.uk/files/advice/selexipag_Uptravi_FINAL_June_2017_for_website_amended_10.08.17.pdf">http://www.scottishmedicines.org.uk/files/advice/selexipag_Uptravi_FINAL_June_2017_for_website_amended_10.08.17.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>Sofosbuvir and Velpatasvir</b> tablets Epclusa® 1195/16	Treatment of chronic hepatitis C virus (HCV) infection in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1195_16_sofosbuvir_velpatasvir_Epclusa/sofosbuvir_velpatasvir_Epclusa">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1195_16_sofosbuvir_velpatasvir_Epclusa/sofosbuvir_velpatasvir_Epclusa</a>	Routinely available in line with national guidance	12/12/2016
<b>Sorafenib</b> tablets Nexavar® 482/08	Treatment of hepatocellular carcinoma	Routinely available in line with local or regional guidance	22/02/2016
<b>Sufentanil citrate</b> sublingual tablets Zalviso® 1270/17	Management of acute moderate to severe post-operative pain in adult patients.  <a href="http://www.scottishmedicines.org.uk/files/advice/sufentanil_Zalviso_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/sufentanil_Zalviso_Non_Sub_FINAL_July_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Talimogene laherparepvec</b> injection Imlygic® 1248/17	Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1248_17_talimogene_laherparepvec_Imlygic/talimogene_laherparepvec_Imlygic_Non_S">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1248_17_talimogene_laherparepvec_Imlygic/talimogene_laherparepvec_Imlygic_Non_S</a>	Not routinely available as not recommended for use in NHSScotland	19/06/2017
<b>Teduglutide</b> injection Revestive® 1139/16	Treatment of adult patients with Short Bowel Syndrome	Not routinely available as not recommended for use in NHSScotland	22/02/2016
<b>Tenofovir alafenamide</b> tablets Vemlidy® 1238/17	Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).	Not routinely available as not recommended for use in NHSScotland	24/04/2017
<b>Ticagrelor</b> tablets Brilique® 1224/17	Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.	Not routinely available as not recommended for use in NHSScotland	24/04/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Tocilizumab</b> injection RoActemra® 1201/16  <a href="http://www.scottishmedicines.org.uk/files/advice/tocilizumab_RoActemra_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/tocilizumab_RoActemra_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>	Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.	Not routinely available as not recommended for use in NHSScotland	10/10/2016
<b>Tolvaptan</b> tablets Jinarc® 1114/15	To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.	Routinely available in line with national guidance	22/02/2016
<b>Topotecan,Caelyx,paclitaxel, trabectedin,gemcitabin</b>  NICE MTA 389  <a href="https://www.nice.org.uk/guidance/ta389">https://www.nice.org.uk/guidance/ta389</a>	Recurrent ovarian cancer	Routinely available in line with national guidance	13/06/2016
<b>Trametinib</b> tablets Mekinist® 1161/16  <a href="http://www.scottishmedicines.org.uk/files/advice/trametinib_0_5mg_and_2mg_Mekinist_FINAL_August_2016_Amended_02.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/trametinib_0_5mg_and_2mg_Mekinist_FINAL_August_2016_Amended_02.09.16_for_website.pdf</a>	In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation	Routinely available in line with local or regional guidance	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Trametinib</b> tablets Mekinist® 1264/17	in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation  <a href="http://www.scottishmedicines.org.uk/files/advice/trametinib_Mekinist_Non_Submission_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/trametinib_Mekinist_Non_Submission_FINAL_June_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>Trastuzumab emtansine</b> infusion Kadcyla® 990/14	As a single agent, for the treatment of adult patients with human epidermal growth factor type 2 (HER2)-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.	Routinely available in line with local or regional guidance	24/04/2017
<b>Trifluridine/tipiracil hydrochloride</b> tablets Lonsurf® 1221/17	Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1221_17_trifluridine_tipiracil_as_hydrochloride_Lonsurf/trifluridine_tipiracil_as_hydrochloride">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1221_17_trifluridine_tipiracil_as_hydrochloride_Lonsurf/trifluridine_tipiracil_as_hydrochloride</a>	Routinely available in line with local or regional guidance	20/02/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Ulipristal acetate</b> tablet Esmya® 1128/16</p>	<p>Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.</p>	<p>Routinely available in line with national guidance</p>	<p>22/02/2016</p>
<p><b>Ustekinumab</b> infusion, injection Stelara® 1250/17</p>	<p>for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist or have medical contraindications to such therapies.</p>	<p>Routinely available in line with national guidance</p>	<p>28/08/2017</p>
<p><b>Ustekinumab</b> injection and prefilled syringe Stelara® 1115/15</p>	<p>Treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p>	<p>Routinely available in line with national guidance</p>	<p>22/02/2016</p>
<p><b>Venetoclax</b> tablets Venclyxto® 1249/17</p>	<p>as monotherapy for the treatment of chronic lymphocytic leukaemia (CLL) either in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>28/08/2017</p>

[http://www.scottishmedicines.org.uk/files/advice/ustekinumab\\_Stelara\\_FINAL\\_June\\_2017\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/ustekinumab_Stelara_FINAL_June_2017_for_website.pdf)

[http://www.scottishmedicines.org.uk/files/advice/venetoclax\\_Venclyxto\\_FINAL\\_July\\_2017\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/venetoclax_Venclyxto_FINAL_July_2017_for_website.pdf)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Vernakalant</b> infusion <b>Brinavess®</b> 1222/17	Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults - For non-surgery patients: atrial fibrillation ≤ 7 days duration - For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1222_17_vernakalant_Brinavess/vernakalant_Brinavess">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1222_17_vernakalant_Brinavess/vernakalant_Brinavess</a>	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Vortioxetine</b> tablets <b>Brintellix®</b> 1158/16	Treatment of major depressive episodes in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1158_16_vortioxetine_Brintellix/vortioxetine_Brintellix">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1158_16_vortioxetine_Brintellix/vortioxetine_Brintellix</a>	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	22/08/2016